-- MediSwitch Drug Interactions Import (Part 104/112)
INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(2576, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(2576, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(2576, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(2576, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(2576, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(2576, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(2576, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(2576, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(2576, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(2576, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(2576, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(2576, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(2576, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2576, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2576, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(2576, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(2576, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(2576, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(2576, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(2576, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2576, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(2576, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(2576, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(2576, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(2576, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(2576, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(2576, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(2576, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(2576, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(2576, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2576, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(2576, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(2576, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(2576, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2576, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(2576, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(2576, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(2576, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2576, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(2576, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(2576, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2576, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2576, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(2576, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(2576, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(2576, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(2576, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(2576, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2576, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2576, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(2576, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(2576, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2576, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2576, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2576, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2576, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(2576, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(2576, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2576, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(2576, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(2576, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(2576, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(2576, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(2576, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(2576, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(2576, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(2576, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(2576, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(2576, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(2576, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(2576, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(2576, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(2576, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(2576, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(2576, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(2576, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(2576, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(2576, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(2576, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(2576, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(19963, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(19963, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(19963, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19963, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19963, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(19963, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(19963, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(19963, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(19963, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(19963, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19963, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(19963, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(19963, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(19963, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(19963, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(19963, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(19963, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(19963, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(19963, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(19963, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(19963, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19963, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19963, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19963, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(19963, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(19963, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(19963, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(19963, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(19963, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19963, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(19963, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(19963, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(19963, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19963, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19963, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(19963, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(19963, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(19963, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(19963, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19963, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(19963, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(19963, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(19963, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19963, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(19963, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(19963, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19963, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19963, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(19963, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(19963, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19963, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19963, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(19963, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(19963, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19963, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(19963, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(19963, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19963, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19963, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(19963, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(19963, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19963, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19963, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19963, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19963, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19963, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(19963, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19963, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(19963, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(19963, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(19963, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(19963, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(19963, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(19963, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(19963, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(19963, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(19963, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(19963, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(19963, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(19963, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(19963, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(19963, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(19963, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(19963, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(19963, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19963, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(19963, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(19963, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(19963, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(20835, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(20835, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(20835, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(20835, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(20835, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(20835, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(20835, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(20835, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(20835, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(20835, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(20835, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(20835, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(20835, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(20835, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(20835, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(20835, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(20835, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(20835, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(20835, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(20835, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(20835, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(20835, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(20835, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(20835, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(20835, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(20835, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(20835, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(20835, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(20835, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(20835, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(20835, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(20835, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(20835, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(20835, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(20835, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(20835, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(20835, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(20835, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(20835, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(20835, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(20835, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(20835, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(20835, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(20835, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(20835, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(20835, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(20835, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(20835, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(20835, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(20835, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(20835, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(20835, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(20835, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(20835, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(20835, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(20835, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(20835, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(20835, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(20835, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(20835, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(20835, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(20835, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(20835, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(20835, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(20835, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(20835, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(20835, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(20835, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(20835, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(20835, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(20835, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(20835, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(20835, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(20835, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(20835, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(20835, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(20835, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(20835, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(20835, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(20835, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(20835, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(20835, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(20835, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(20835, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(20835, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(20835, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(20835, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(20835, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(20835, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(15458, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(15458, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(15458, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(15458, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(15458, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(15458, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(15458, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(15458, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(15458, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(15458, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(15458, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(15458, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(15458, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(15458, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(15458, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(15458, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(15458, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(15458, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(15458, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(15458, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(15458, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(15458, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(15458, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(15458, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(15458, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(15458, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(15458, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(15458, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(15458, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(15458, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(15458, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(15458, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(15458, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(15458, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(15458, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(15458, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(15458, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(15458, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(15458, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(15458, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(15458, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(15458, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(15458, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(15458, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(15458, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(15458, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(15458, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(15458, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(15458, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(15458, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(15458, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(15458, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(15458, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(15458, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(15458, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(15458, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(15458, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(15458, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(15458, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(15458, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(15458, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(15458, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(15458, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(15458, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(15458, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(15458, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(15458, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(15458, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(15458, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(15458, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(15458, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(15458, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(15458, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(15458, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(15458, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(15458, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(15458, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(15458, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(15458, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(15458, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(15458, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(15458, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(15458, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(15458, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(15458, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(15458, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(15458, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(15458, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(15458, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(26572, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(26572, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(26572, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(26572, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(26572, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(26572, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(26572, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(26572, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(26572, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(26572, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(26572, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(26572, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(26572, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(26572, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(26572, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(26572, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26572, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(26572, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(26572, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(26572, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(26572, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(26572, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(26572, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(26572, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(26572, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(26572, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(26572, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(26572, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(26572, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(26572, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(26572, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(26572, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(26572, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(26572, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(26572, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(26572, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(26572, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(26572, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(26572, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(26572, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(26572, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(26572, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(26572, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(26572, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(26572, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(26572, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(26572, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(26572, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(26572, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(26572, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(26572, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(26572, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(26572, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26572, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(26572, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(26572, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(26572, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(26572, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(26572, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(26572, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26572, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(26572, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(26572, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(26572, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(26572, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(26572, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(26572, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(26572, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(26572, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(26572, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(26572, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(26572, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(26572, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(26572, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(26572, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(26572, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(26572, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(26572, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(26572, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(26572, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(26572, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(26572, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(26572, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(26572, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(26572, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(26572, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(26572, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(26572, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(26572, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(31661, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(31661, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(31661, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(31661, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(31661, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(31661, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(31661, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(31661, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(31661, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(31661, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(31661, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(31661, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(31661, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(31661, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(31661, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(31661, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(31661, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(31661, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(31661, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(31661, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(31661, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(31661, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(31661, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(31661, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(31661, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(31661, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(31661, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(31661, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(31661, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(31661, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(31661, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(31661, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(31661, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(31661, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(31661, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(31661, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(31661, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(31661, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(31661, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(31661, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(31661, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(31661, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(31661, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(31661, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(31661, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(31661, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(31661, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(31661, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(31661, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(31661, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(31661, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(31661, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(31661, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(31661, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(31661, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(31661, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(31661, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(31661, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(31661, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(31661, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(31661, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(31661, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(31661, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(31661, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(31661, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(31661, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(31661, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(31661, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(31661, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(31661, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(31661, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(31661, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(31661, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(31661, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(31661, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(31661, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(31661, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(31661, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(31661, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(31661, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(31661, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(31661, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(31661, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(31661, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(31661, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(31661, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(31661, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(31661, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(31661, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(19825, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(19825, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(19825, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19825, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19825, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(19825, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(19825, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(19825, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(19825, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(19825, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19825, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(19825, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(19825, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(19825, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(19825, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(19825, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(19825, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(19825, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(19825, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(19825, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(19825, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19825, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19825, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19825, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(19825, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(19825, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(19825, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(19825, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(19825, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19825, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(19825, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(19825, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(19825, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19825, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19825, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(19825, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(19825, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(19825, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(19825, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19825, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(19825, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(19825, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(19825, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19825, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(19825, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(19825, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19825, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19825, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(19825, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(19825, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19825, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19825, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(19825, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(19825, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19825, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(19825, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(19825, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19825, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19825, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(19825, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(19825, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19825, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19825, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19825, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19825, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19825, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(19825, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19825, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(19825, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(19825, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(19825, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(19825, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(19825, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(19825, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(19825, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(19825, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(19825, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(19825, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(19825, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(19825, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(19825, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(19825, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(19825, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(19825, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(19825, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19825, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(19825, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(19825, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(19825, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(22500, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(22500, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(22500, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(22500, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(22500, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(22500, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(22500, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(22500, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(22500, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(22500, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(22500, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(22500, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(22500, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(22500, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(22500, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(22500, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(22500, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(22500, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(22500, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(22500, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(22500, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(22500, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22500, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22500, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(22500, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(22500, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(22500, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(22500, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(22500, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22500, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(22500, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(22500, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(22500, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(22500, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(22500, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(22500, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(22500, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(22500, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(22500, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22500, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(22500, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(22500, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(22500, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22500, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(22500, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(22500, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(22500, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22500, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(22500, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(22500, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22500, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22500, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(22500, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(22500, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(22500, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(22500, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(22500, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22500, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22500, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(22500, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(22500, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22500, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22500, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22500, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22500, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(22500, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(22500, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22500, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(22500, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(22500, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(22500, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(22500, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(22500, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(22500, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(22500, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(22500, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(22500, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(22500, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(22500, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(22500, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(22500, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(22500, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(22500, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(22500, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(22500, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(22500, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(22500, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(22500, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(22500, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(32289, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(32289, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(32289, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(32289, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(32289, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(32289, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(32289, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(32289, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(32289, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(32289, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(32289, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(32289, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(32289, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(32289, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(32289, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(32289, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(32289, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(32289, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(32289, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(32289, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(32289, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(32289, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32289, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32289, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(32289, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(32289, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(32289, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(32289, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(32289, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32289, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(32289, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(32289, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(32289, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(32289, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(32289, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(32289, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(32289, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(32289, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(32289, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32289, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(32289, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(32289, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(32289, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32289, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(32289, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(32289, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(32289, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32289, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(32289, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(32289, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(32289, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(32289, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(32289, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(32289, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(32289, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(32289, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(32289, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(32289, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(32289, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(32289, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(32289, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(32289, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(32289, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(32289, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32289, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(32289, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(32289, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32289, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(32289, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(32289, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(32289, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(32289, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(32289, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(32289, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(32289, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(32289, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(32289, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(32289, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(32289, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(32289, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(32289, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(32289, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(32289, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(32289, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(32289, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(32289, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(32289, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(32289, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(32289, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(17551, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(17551, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(17551, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(17551, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(17551, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(17551, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(17551, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(17551, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(17551, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(17551, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(17551, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(17551, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(17551, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(17551, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(17551, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(17551, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(17551, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(17551, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(17551, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(17551, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(17551, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(17551, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(17551, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(17551, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(17551, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(17551, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(17551, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(17551, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(17551, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(17551, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(17551, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(17551, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(17551, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(17551, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(17551, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(17551, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(17551, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(17551, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(17551, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(17551, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(17551, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(17551, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(17551, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(17551, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(17551, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(17551, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17551, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(17551, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(17551, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(17551, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(17551, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(17551, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(17551, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(17551, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(17551, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(17551, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(17551, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(17551, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(17551, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(17551, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(17551, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(17551, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(17551, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(17551, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(17551, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(17551, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(17551, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(17551, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(17551, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(17551, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(17551, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(17551, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(17551, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(17551, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(17551, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(17551, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(17551, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(17551, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(17551, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(17551, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(17551, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(17551, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(17551, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(17551, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(17551, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(17551, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(17551, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(17551, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(17551, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(2579, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(2579, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(2579, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(2579, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(2579, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(2579, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(2579, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(2579, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(2579, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(2579, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(2579, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(2579, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(2579, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(2579, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(2579, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(2579, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(2579, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(2579, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(2579, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(2579, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(2579, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(2579, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2579, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2579, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(2579, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(2579, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(2579, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(2579, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(2579, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2579, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(2579, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(2579, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(2579, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(2579, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(2579, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(2579, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(2579, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(2579, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(2579, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2579, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(2579, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(2579, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(2579, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2579, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(2579, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(2579, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(2579, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2579, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(2579, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(2579, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2579, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2579, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(2579, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(2579, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(2579, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(2579, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(2579, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2579, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2579, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(2579, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(2579, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2579, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2579, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(2579, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2579, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(2579, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(2579, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(2579, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(2579, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(2579, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(2579, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(2579, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(2579, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(2579, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(2579, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(2579, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(2579, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(2579, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(2579, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(2579, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(2579, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(2579, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(2579, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(2579, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(2579, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(2579, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(2579, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(2579, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(2579, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(7386, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(7386, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(7386, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(7386, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(7386, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(7386, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(7386, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(7386, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(7386, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(7386, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(7386, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(7386, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(7386, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(7386, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(7386, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(7386, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(7386, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(7386, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(7386, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(7386, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(7386, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(7386, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(7386, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(7386, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(7386, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(7386, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(7386, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(7386, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(7386, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(7386, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(7386, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(7386, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(7386, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(7386, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(7386, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(7386, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(7386, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(7386, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(7386, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(7386, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(7386, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(7386, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(7386, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(7386, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(7386, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(7386, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(7386, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(7386, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(7386, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(7386, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(7386, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(7386, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(7386, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(7386, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(7386, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(7386, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(7386, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(7386, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(7386, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(7386, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(7386, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(7386, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(7386, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(7386, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(7386, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(7386, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(7386, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(7386, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(7386, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(7386, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(7386, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(7386, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(7386, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(7386, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(7386, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(7386, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(7386, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(7386, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(7386, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(7386, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(7386, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(7386, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(7386, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(7386, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(7386, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(7386, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(7386, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(7386, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(7386, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(22499, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(22499, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(22499, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(22499, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(22499, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(22499, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(22499, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(22499, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(22499, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(22499, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(22499, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(22499, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(22499, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(22499, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(22499, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(22499, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(22499, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(22499, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(22499, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(22499, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(22499, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(22499, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22499, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22499, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(22499, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(22499, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(22499, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(22499, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(22499, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22499, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(22499, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(22499, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(22499, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(22499, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(22499, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(22499, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(22499, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(22499, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(22499, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22499, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(22499, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(22499, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(22499, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22499, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(22499, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(22499, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(22499, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22499, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(22499, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(22499, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22499, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22499, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(22499, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(22499, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(22499, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(22499, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(22499, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22499, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22499, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(22499, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(22499, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22499, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22499, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(22499, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22499, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(22499, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(22499, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(22499, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(22499, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(22499, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(22499, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(22499, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(22499, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(22499, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(22499, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(22499, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(22499, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(22499, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(22499, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(22499, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(22499, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(22499, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(22499, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(22499, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(22499, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(22499, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(22499, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(22499, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(22499, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(25216, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(25216, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(25216, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(25216, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(25216, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(25216, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(25216, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(25216, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25216, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(25216, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(25216, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(25216, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(25216, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(25216, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(25216, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(25216, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(25216, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(25216, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(25216, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(25216, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(25216, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(25216, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25216, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25216, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(25216, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(25216, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(25216, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(25216, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(25216, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25216, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(25216, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(25216, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(25216, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(25216, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(25216, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(25216, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(25216, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(25216, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(25216, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25216, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(25216, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(25216, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(25216, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25216, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(25216, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(25216, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(25216, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25216, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(25216, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(25216, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25216, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25216, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(25216, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(25216, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(25216, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(25216, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(25216, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25216, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25216, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(25216, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(25216, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25216, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25216, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25216, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25216, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(25216, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(25216, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25216, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(25216, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(25216, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(25216, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(25216, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(25216, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(25216, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(25216, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(25216, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(25216, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(25216, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(25216, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(25216, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(25216, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(25216, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(25216, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(25216, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(25216, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(25216, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(25216, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(25216, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(25216, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(30474, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(30474, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(30474, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30474, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30474, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(30474, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(30474, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(30474, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(30474, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(30474, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30474, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(30474, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(30474, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(30474, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(30474, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(30474, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(30474, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(30474, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(30474, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(30474, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(30474, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30474, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30474, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30474, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(30474, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(30474, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(30474, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(30474, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(30474, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30474, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(30474, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(30474, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(30474, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30474, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30474, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(30474, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(30474, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(30474, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(30474, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30474, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(30474, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(30474, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(30474, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30474, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(30474, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(30474, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(30474, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30474, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(30474, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(30474, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30474, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30474, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(30474, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(30474, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30474, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(30474, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(30474, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30474, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30474, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(30474, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(30474, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30474, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30474, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(30474, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30474, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30474, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(30474, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30474, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(30474, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(30474, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30474, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(30474, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(30474, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(30474, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30474, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(30474, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(30474, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(30474, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(30474, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(30474, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(30474, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(30474, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30474, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(30474, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(30474, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30474, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(30474, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30474, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(30474, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(19842, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(19842, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(19842, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19842, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19842, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(19842, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(19842, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(19842, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(19842, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(19842, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19842, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(19842, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(19842, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(19842, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(19842, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(19842, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(19842, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(19842, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(19842, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(19842, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(19842, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19842, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19842, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19842, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(19842, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(19842, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(19842, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(19842, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(19842, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19842, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(19842, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(19842, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(19842, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(19842, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19842, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(19842, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(19842, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(19842, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(19842, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19842, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(19842, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(19842, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(19842, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19842, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(19842, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(19842, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19842, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19842, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(19842, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(19842, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19842, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19842, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(19842, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(19842, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19842, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(19842, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(19842, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19842, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19842, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(19842, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(19842, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19842, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19842, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(19842, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19842, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19842, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(19842, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19842, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(19842, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(19842, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(19842, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(19842, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(19842, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(19842, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(19842, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(19842, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(19842, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(19842, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(19842, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(19842, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(19842, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(19842, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(19842, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(19842, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(19842, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(19842, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(19842, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(19842, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(19842, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(27605, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(27605, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(27605, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(27605, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(27605, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(27605, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(27605, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(27605, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(27605, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(27605, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(27605, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(27605, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(27605, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(27605, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(27605, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(27605, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(27605, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(27605, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(27605, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(27605, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(27605, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(27605, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27605, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27605, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(27605, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(27605, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(27605, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(27605, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(27605, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27605, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(27605, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(27605, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(27605, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(27605, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(27605, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(27605, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(27605, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(27605, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(27605, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27605, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(27605, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(27605, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(27605, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27605, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(27605, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(27605, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(27605, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27605, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(27605, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(27605, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27605, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27605, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(27605, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(27605, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(27605, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(27605, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(27605, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27605, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27605, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(27605, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(27605, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27605, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27605, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27605, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27605, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(27605, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(27605, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27605, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(27605, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(27605, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(27605, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(27605, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(27605, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(27605, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(27605, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(27605, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(27605, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(27605, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(27605, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(27605, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(27605, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(27605, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(27605, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(27605, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(27605, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27605, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(27605, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(27605, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(27605, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(30473, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(30473, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(30473, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30473, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30473, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(30473, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(30473, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(30473, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(30473, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(30473, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30473, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(30473, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(30473, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(30473, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(30473, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(30473, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(30473, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(30473, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(30473, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(30473, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(30473, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30473, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30473, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30473, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(30473, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(30473, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(30473, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(30473, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(30473, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30473, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(30473, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(30473, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(30473, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30473, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30473, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(30473, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(30473, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(30473, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(30473, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30473, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(30473, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(30473, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(30473, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30473, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(30473, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(30473, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(30473, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30473, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(30473, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(30473, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30473, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30473, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(30473, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(30473, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30473, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(30473, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(30473, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30473, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30473, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(30473, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(30473, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30473, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30473, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30473, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30473, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30473, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(30473, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30473, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(30473, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(30473, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30473, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(30473, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(30473, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(30473, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30473, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(30473, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(30473, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(30473, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(30473, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(30473, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(30473, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(30473, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30473, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(30473, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(30473, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30473, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(30473, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30473, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(30473, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(30476, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(30476, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(30476, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30476, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30476, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(30476, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(30476, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(30476, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(30476, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(30476, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30476, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(30476, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(30476, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(30476, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(30476, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(30476, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(30476, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(30476, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(30476, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(30476, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(30476, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30476, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30476, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30476, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(30476, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(30476, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(30476, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(30476, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(30476, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30476, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(30476, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(30476, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(30476, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(30476, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30476, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(30476, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(30476, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(30476, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(30476, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30476, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(30476, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(30476, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(30476, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30476, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(30476, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(30476, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(30476, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30476, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(30476, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(30476, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30476, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30476, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(30476, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(30476, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30476, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(30476, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(30476, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30476, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30476, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(30476, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(30476, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30476, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30476, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(30476, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30476, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30476, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(30476, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(30476, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(30476, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(30476, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30476, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(30476, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(30476, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(30476, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30476, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(30476, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(30476, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(30476, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(30476, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(30476, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(30476, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(30476, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30476, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(30476, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(30476, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(30476, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(30476, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(30476, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(30476, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(25129, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(25129, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(25129, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(25129, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(25129, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(25129, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(25129, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(25129, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25129, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(25129, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(25129, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(25129, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(25129, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(25129, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(25129, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(25129, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(25129, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(25129, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(25129, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(25129, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(25129, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(25129, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25129, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25129, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(25129, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(25129, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(25129, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(25129, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(25129, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25129, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(25129, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(25129, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(25129, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(25129, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(25129, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(25129, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(25129, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(25129, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(25129, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25129, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(25129, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(25129, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(25129, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25129, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(25129, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(25129, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(25129, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25129, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(25129, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(25129, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25129, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25129, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(25129, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(25129, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(25129, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(25129, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(25129, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25129, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25129, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(25129, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(25129, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25129, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25129, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(25129, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25129, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(25129, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(25129, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(25129, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(25129, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(25129, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(25129, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(25129, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(25129, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(25129, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(25129, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(25129, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(25129, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(25129, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(25129, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(25129, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(25129, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(25129, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(25129, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(25129, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(25129, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(25129, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(25129, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(25129, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(25129, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(27817, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(27817, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(27817, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(27817, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(27817, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(27817, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(27817, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(27817, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(27817, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(27817, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(27817, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(27817, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(27817, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(27817, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(27817, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(27817, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(27817, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(27817, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(27817, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(27817, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(27817, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(27817, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27817, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27817, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(27817, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(27817, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(27817, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(27817, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(27817, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27817, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(27817, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(27817, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(27817, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(27817, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(27817, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(27817, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(27817, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(27817, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(27817, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27817, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(27817, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(27817, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(27817, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27817, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(27817, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(27817, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(27817, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27817, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(27817, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(27817, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27817, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27817, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(27817, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(27817, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(27817, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(27817, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(27817, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27817, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27817, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(27817, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(27817, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27817, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27817, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(27817, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27817, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(27817, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(27817, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(27817, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(27817, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(27817, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(27817, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(27817, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(27817, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(27817, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(27817, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(27817, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(27817, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(27817, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(27817, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(27817, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(27817, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(27817, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(27817, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(27817, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(27817, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(27817, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(27817, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(27817, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(27817, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(10866, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(10866, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(10866, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(10866, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(10866, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(10866, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(10866, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(10866, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(10866, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(10866, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(10866, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(10866, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(10866, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(10866, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(10866, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(10866, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(10866, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(10866, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(10866, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(10866, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(10866, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(10866, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(10866, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(10866, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(10866, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(10866, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(10866, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(10866, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(10866, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(10866, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(10866, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(10866, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(10866, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(10866, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(10866, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(10866, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(10866, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(10866, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(10866, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(10866, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(10866, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(10866, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(10866, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(10866, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(10866, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(10866, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(10866, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(10866, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(10866, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(10866, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(10866, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(10866, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(10866, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(10866, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(10866, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(10866, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(10866, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(10866, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(10866, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(10866, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(10866, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(10866, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(10866, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(10866, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(10866, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(10866, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(10866, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(10866, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(10866, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(10866, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(10866, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(10866, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(10866, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(10866, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(10866, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(10866, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(10866, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(10866, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(10866, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(10866, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(10866, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(10866, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(10866, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(10866, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(10866, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(10866, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(10866, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(10866, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(10866, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(3119, 'metformin hydrochloride', 'N/A', 'major', 'Drug Interactions (clinical evaluation of drug interactions conducted with metformin) Glyburide: In a single-dose interaction study in type 2 diabetes subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride and Oral Sulfonylurea Therapy in Adult Patients).Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide i', 'DailyMed'),
(3119, 'cephalexin', 'N/A', 'moderate', 'Drug Interactions Metformin— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.', 'DailyMed'),
(3119, 'glyburide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(3119, 'glipizide and metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glipizide and metformin hydrochloride tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glipizide and metformin hydrochloride tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(3119, 'nifedipine', 'N/A', 'minor', 'Metformin: A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in urine. Nifedipine appears to enhance the absorption of metformin.', 'DailyMed'),
(3119, 'pioglitazone hydrochloride', 'N/A', 'minor', 'Metformin: Co-administration of a single dose of metformin (1000 mg) and ACTOS after 7 days of ACTOS did not alter the pharmacokinetics of the single dose of metformin.', 'DailyMed'),
(3119, 'glyburide', 'N/A', 'minor', 'Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. Coadministration of glyburide and metformin did not result in any changes in either metformin pharmacokinetics or pharmacodynamics.', 'DailyMed'),
(3119, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(3119, 'topiramate', 'N/A', 'contraindicated', 'Metformin is contraindicated with metabolic acidosis, a possible effect of topiramate (7.4) Lithium levels should be monitored when co-administered with high-dose topiramate (7.5) Other Carbonic Anhydrase Inhibitors: monitor the patient for the appearance or worsening of metabolic acidosis (7.6) 7.1 Antiepileptic Drugs Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.5)].', 'DailyMed'),
(3119, 'glyburide and metformin', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving glyburide and metformin, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving glyburide and metformin, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(3119, 'colesevelam hydrochloride', 'N/A', 'minor', 'Drugs with a known interaction with colesevelam Cyclosporinec, glyburidea, levothyroxinea, and oral contraceptives containing ethinyl estradiol and norethindronea Drugs with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam based on in vitro or in vivo testing cephalexin, ciprofloxacin, digoxin, warfarinb fenofibrate, lovastatin, metformin, metoprolol, pioglitazone, quinidine, repaglinide, valproic acid, verapamil In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels.', 'DailyMed'),
(3119, 'metformin hydrochloride, tyrosine', 'N/A', 'minor', 'Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with metformin) GlyburideIn a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP and Oral Sulfonylurea Therapy in Adult Patients). FurosemideA single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration.', 'DailyMed'),
(3119, 'pioglitazone hydrochloride and metformin hydrochloride', 'N/A', 'moderate', 'Drug-Drug Interactions Co-administration of a single dose of metformin (1000 mg) and pioglitazone after 7 days of pioglitazone (45 mg) did not alter the pharmacokinetics of the single dose of metformin. Specific pharmacokinetic drug interaction studies with ACTOPLUS MET have not been performed, although such studies have been conducted with the individual pioglitazone and metformin components. Metformin hydrochloride See PRECAUTIONS, Drug Interactions, Metformin hydrochloride', 'DailyMed'),
(3119, 'nateglinide', 'N/A', 'minor', 'Metformin: When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.', 'DailyMed'),
(3119, 'lacosamide', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, or an oral contraceptive containing ethinylestradiol and levonorgestrel.', 'DailyMed'),
(3119, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Metformin treatment in individuals with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(3119, 'rosiglitazone maleate and metformin hydrochloride', 'N/A', 'moderate', '[See Clinical Pharmacology (12.4).] 7.2 Cationic Drugs Although drug interactions for metformin with cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of AVANDAMET and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.', 'DailyMed'),
(3119, 'sulfamethoxazole and trimethoprim', 'N/A', 'minor', 'Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.', 'DailyMed'),
(3119, 'metformin hydrochloride er', 'N/A', 'minor', 'DRUG INTERACTIONS Glyburide: In a single-dose interaction study in type 2 diabetes patients, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets, USP or Metformin Hydrochloride Extended-release Tablets, USP and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration.', 'DailyMed'),
(3119, 'digoxin', 'N/A', 'minor', 'Carvedilol 16% 14% Diltiazem 20% NA Indomethacin 40% NA Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20-49% NA Tolvaptan 30% NA Trimethoprim 22-28% NA Digoxin concentrations increased, but magnitude is unclear Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole, rabeprazole, Measure serum digoxin concentrations before initiating concomitant drugs.', 'DailyMed'),
(3119, 'glyburide-metformin hydrochloride', 'N/A', 'minor', 'Drug Interactions Glyburide and Metformin Hydrochloride Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glyburide and Metformin Hydrochloride Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(3119, 'linagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS Cationic drugs eliminated by renal tubular secretion: May reduce metformin elimination. (7.2) 7.1 Drug Interactions with Metformin Cationic Drugs Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. As JENTADUETO is a fixed-dose combination of linagliptin and metformin, use of alternative treatments (not containing linagliptin) is strongly recommended when concomitant treatment with a strong P-gp or CYP 3A4 inducer is necessary [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(3119, 'topiramate tablet', 'N/A', 'contraindicated', 'Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see Clinical Pharmacology (12.3)] 7.4 Metformin Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(3119, 'methaver', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(3119, 'memantine hydrochloride', 'N/A', 'minor', '7.4 Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide.', 'DailyMed'),
(3119, 'ranolazine', 'N/A', 'minor', '(7.2) OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with RANEXA 1000 mg twice daily. Drugs Transported by OCT2 In subjects with type 2 diabetes mellitus, concomitant use of RANEXA 1000 mg twice daily and metformin results in increased plasma levels of metformin. When RANEXA 1000 mg twice daily is co-administered with metformin, metformin dose should not exceed 1700 mg/day.', 'DailyMed'),
(3119, 'pioglitazone and metformin', 'N/A', 'moderate', 'Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.2) •Cationic drugs: May reduce metformin elimination. Use these drugs with caution in patients treated with metformin, as the risk of lactic acidosis may increase.', 'DailyMed'),
(3119, 'metformin hcl', 'N/A', 'minor', 'DRUG INTERACTIONS (Clinical Evaluation of Drug Interactions Conducted with Metformin Hydrochloride Tablets USP) Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Metformin Hydrochloride Tablets USP and Oral Sulfonylurea Therapy in Adult Patients). Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affecte', 'DailyMed'),
(3119, 'trospium chloride', 'N/A', 'minor', '(7.2) Concomitant use with metformin immediate release tablets reduced exposure and peak concentration of trospium. 7.4 Metformin Co-administration of 500 mg metformin immediate release tablets twice daily with trospium chloride 60 mg extended release reduced the steady-state systemic exposure of trospium by approximately 29% for mean AUC0-24 and by 34% for mean Cmax [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(3119, 'dolutegravir sodium', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 6) [see Contraindications (4), Drug Interactions (7.3)]. Metformin ↑Metformin With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment.', 'DailyMed'),
(3119, 'miglitol', 'N/A', 'major', 'The effect of miglitol (100 mg 3 times daily for 7 days) on the pharmacokinetics of a single 1000 mg dose of metformin was investigated in healthy volunteers. Mean AUC and C max values for metformin were 12% to 13% lower when the volunteers were given miglitol as compared with placebo, but this difference was not statistically significant.', 'DailyMed'),
(3119, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', 'Drug Interactions The concomitant use of JANUMET XR with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7)].', 'DailyMed'),
(3119, 'glipizide and metformin hcl', 'N/A', 'minor', 'Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia.', 'DailyMed'),
(3119, 'metformin hydrochloride extended-release tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(3119, 'midodrine hydrochloride', 'N/A', 'minor', 'Potential for Drug Interaction It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desyglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretionof such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.', 'DailyMed'),
(3119, 'glycopyrrolate', 'N/A', 'moderate', '• Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted. ( 7) • Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin.', 'DailyMed'),
(3119, 'dofetilide', 'N/A', 'minor', 'In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin, and amiloride) should be co-administered with care as they might increase dofetilide levels.', 'DailyMed'),
(3119, 'ertugliflozin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risk', 'DailyMed'),
(3119, 'colesevelam hcl', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochoride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact: In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(3119, 'iodixanol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, VISIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(3119, 'sodium zirconium cyclosilicate', 'N/A', 'minor', 'Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor).', 'DailyMed'),
(3119, 'ioversol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(3119, 'colesevelam', 'N/A', 'minor', 'Concomitant use with colesevelam hydrochloride may increase the exposure of the following drugs: Metformin extended release. 7.2 Colesevelam Hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Table 5 Colesevelam hydrochloride Drug Interactions that Increase the Exposure of the Concomitant Medication Metformin Extended-Release (ER) Clinical Impact In vivo drug interactions studies showed an increase in metformin extended release (ER) when coadministered with colesevelam hydrochloride [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(3119, 'alogliptin and metformin hydrochloride', 'N/A', 'minor', '(7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. (7) Alcohol can potentiate the effect of metformin on lactate metabolism. (7) Metformin Hydrochloride Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.', 'DailyMed'),
(3119, 'emtricitabine, rilpivirine, and tenofovir alafenamide', 'N/A', 'major', '7.5 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been either observed or expected when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, buprenorphine, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, lorazepam, metformin, midazolam, naloxone, norbuprenorphine, norethindrone, norgestimate/ethinyl estradiol, sildenafil, simeprevir, sofosbuvir, and velpatasvir.', 'DailyMed'),
(3119, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(3119, 'doravirine', 'N/A', 'major', '7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(3119, 'glycopyrrolate oral solution', 'N/A', 'moderate', 'Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.', 'DailyMed'),
(3119, 'bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate', 'N/A', 'minor', 'Metformin ↑ Metformin Refer to the prescribing information of metformin for assessing the benefit and risk of concomitant use of BIKTARVY and metformin.', 'DailyMed'),
(3119, 'linagliptin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(3119, 'empagliflozin, linagliptin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(3119, 'iohexol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(3119, 'mavorixafor', 'N/A', 'moderate', 'Metformin: Monitor for glycemic control and adjust the dose of metformin as necessary. Mavorixafor may decrease the mean C maxand AUC of metformin, which may reduce metformin''s effectiveness.', 'DailyMed'),
(3119, 'metformin hydrochloride tablets', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(3119, 'betamethasone sodium phosphate, betamethasone acetate, lidocaine, iodixanol, povidine iodine', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(3119, 'tafenoquine', 'N/A', 'minor', 'Avoid coadministration of ARAKODA with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(3119, 'saxagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(3119, 'dapagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors, such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(3119, 'patiromer', 'N/A', 'major', 'Table 2: Clinically important drug interactions of Veltassa Angiotensin II receptor blockers (ARB) Telmisartan β-adrenoceptor blockers (β-blocker) Bisoprolol, carvedilol, nebivolol Antibiotics Ciprofloxacin Anti-Parathyroid Agents and Thyroid Preparations Levothyroxine Blood Glucose Lowering Drugs Metformin Immunosuppressants Mycophenolate mofetil Others Quinidine, thiamine 7.2 No Observed Clinically Important Interaction of Veltassa with Other Drugs The binding of the following drugs to patiromer was evaluated [see Clinical Pharmacology (12.3)] and no clinically significant binding was observed.', 'DailyMed'),
(3119, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Metformin treatment in patients with type 2 diabetes decreases serum folate. Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(3119, 'empagliflozin, metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(3119, 'empagliflozin and metformin hydrochloride', 'N/A', 'minor', 'Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. (7) Drugs that Reduce Metformin Clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(3119, 'saxagliptin and metformin', 'N/A', 'major', '7 DRUG INTERACTIONS • Strong CYP3A4/5 inhibitors (e.g., ketoconazole): Coadministration with saxagliptin and metformin hydrochloride extended-release tablets significantly increases saxagliptin concentrations. Limit saxagliptin and metformin hydrochloride extended-release tablets dosage to 2.5 mg/1,000 mg once daily when coadministered with a strong CYP3A4/5 inhibitor. (7.2) • Drugs that reduce metformin clearance: May increase risk of lactic acidosis.', 'DailyMed'),
(3119, 'pioglitazone and metformin hydrochloride', 'N/A', 'minor', '(7.3) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of ACTOPLUS MET is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOPLUS MET, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of ACTOPLUS MET (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(3119, 'metformin hydrochloride extended-release', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 2: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(3119, 'metformin', 'N/A', 'major', 'Consider more frequent monitoring ( 7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use ( 7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake ( 7) Table 2 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets.', 'DailyMed'),
(3119, 'fexinidazole', 'N/A', 'minor', 'Drugs Substrates of OCT2, OAT1, OAT3, MATE1, and MATE2-K Transporters Examples (not fully inclusive): Metformin, dofetilide, adefovir, cefaclor, furosemide Clinical Impact Increased risk for adverse reactions associated with increased concentrations of the drug due to inhibition of these transporters by fexinidazole [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(3119, 'pioglitazole and metformin hydrochloride', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(3119, 'fedratinib hydrochloride', 'N/A', 'moderate', 'Monitor for adverse reactions and consider dose modifications for drugs that are renally excreted via OCT2 or MATE1/2-K (e.g., metformin), as necessary when coadministered with INREBIC.', 'DailyMed'),
(3119, 'emtricitabine, rilpivirine, tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(3119, 'doravirine, lamivudine, and tenofovir disoproxil fumarate', 'N/A', 'major', '7.3 Effect of DELSTRIGO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, or midazolam.', 'DailyMed'),
(3119, 'tafenoquine succinate', 'N/A', 'minor', 'Avoid coadministration of KRINTAFEL with OCT2 and MATE substrates (e.g., dofetilide, metformin).', 'DailyMed'),
(3119, 'iopamidol', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, iopamidol injection administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(3119, 'emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate', 'N/A', 'major', 'RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(3119, 'abacavir sulfate, dolutegravir sodium, lamivudine', 'N/A', 'minor', 'Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications (4), Drug Interactions (7.3)]. Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of TRIUMEQ or TRIUMEQ PD and metformin.', 'DailyMed'),
(3119, 'lumacaftor and ivacaftor', 'N/A', 'minor', 'No dosage adjustment is recommended for metformin.', 'DailyMed'),
(3119, 'dolutegravir sodium and lamivudine', 'N/A', 'minor', '7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4), Clinical Pharmacology (12.3)]. Antidiabetic: Metformina ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.', 'DailyMed'),
(3119, 'dolutegravir sodium and rilpivirine hydrochloride', 'N/A', 'minor', '7.2 Potential for JULUCA to Affect Other Drugs Dolutegravir, a component of JULUCA, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1, thus it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications (4), Drug Interactions (7.4)]. Antidiabetic: Metforminb ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of JULUCA and metformin.', 'DailyMed'),
(3119, 'levoketoconazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV ( 7.1) Sensitive CYP3A4 or CYP3A4 and P-gp Substrates: Concomitant use of RECORLEV with these substrates is contraindicated or not recommended ( 7.1) Atorvastatin: Use lowest atorvastatin dose possible and monitor for adverse reactions for dosages exceeding 20 mg daily ( 7.1) Metformin: Monitor glycemia, kidney function, and vitamin B12 and adjust metformin dosage as needed ( 7.1) Strong CYP3A4 Inhibitors or Inducers: Avoid use of these drugs 2 weeks before and during RECORLEV treatment ( 7.2) Gastric Acid Modulators: See Full Prescribing Information for recommendations regarding concomitant use with RECORLEV ( 7.2) 7.1 Effect of RECORLEV on Other', 'DailyMed'),
(3119, 'iopromide', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents.', 'DailyMed'),
(3119, 'canagliflozin and metformin hydrochloride', 'N/A', 'moderate', 'Examples: Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) Drugs That Reduce Metformin Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin HCl on lactate metabolism. Consider more frequent monitoring ( 7) Drugs that Reduce Metformin Clearance:May increase risk of lactic ac', 'DailyMed'),
(3119, 'rilpivirine hydrochloride', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(3119, 'pioglitazone hcl and metformin hcl', 'N/A', 'minor', '7 DRUG INTERACTIONS • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride tablets dose to 15 mg/850 mg daily. (7.3)• Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)].', 'DailyMed'),
(3119, 'vandetanib', 'N/A', 'minor', '7.2 Effect of CAPRELSA on OCT2 Transporter CAPRELSA increased plasma concentrations of metformin that is transported by the organic cation transporter type 2 (OCT2).', 'DailyMed'),
(3119, 'metformin er  500 mg', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with metformin hydrochloride extended-release tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis.', 'DailyMed'),
(3119, 'metformin hydrochloride tablet', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with metformin hydrochloride tablets may increase the risk for lactic acidosis. Drugs that Reduce metformin hydrochloride tablet Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis ', 'DailyMed'),
(3119, 'cabotegravir and rilpivirine', 'N/A', 'major', 'Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin.', 'DailyMed'),
(3119, 'emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide', 'N/A', 'major', '7.8 Drugs Without Clinically Significant Interactions with ODEFSEY Based on drug interaction studies conducted with the fixed dose combination or components of ODEFSEY, no clinically significant drug interactions have been observed when ODEFSEY is combined with the following drugs: acetaminophen, atorvastatin, chlorzoxazone, digoxin, ethinyl estradiol, ledipasvir, metformin, midazolam, norethindrone, norgestimate, sildenafil, simeprevir, sofosbuvir, velpatasvir, and voxilaprevir.', 'DailyMed'),
(3119, 'risdiplam', 'N/A', 'minor', '(7.1) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3)], such as metformin.', 'DailyMed'),
(29767, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(16355, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(28199, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(24431, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(25534, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(28623, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(6921, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(28590, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(17845, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(30007, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(4298, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(16675, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(11768, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(12707, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(17846, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(3089, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(25533, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(6920, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(17844, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(25647, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(19812, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS · Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution .(7.1) Potential acid-base and electrolyte disturbances. (7.2) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide hydrochloride ophthalmic solution. The concomitant administration of dorzolamide hydrochloride ophthalmic solution and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been rep', 'DailyMed'),
(20678, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Palbociclib is primarily metabolized by CYP3A and sulfotransferase (SULT) enzyme SULT2A1. In vivo, palbociclib is a time-dependent inhibitor of CYP3A. •CYP3A Inhibitors: Avoid concurrent use of IBRANCE with strong CYP3A inhibitors. If the strong inhibitor cannot be avoided, reduce the IBRANCE dose. (2.2, 7.1) •CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (7.2) •CYP3A Substrates: The dose of sensitive CYP3A4 substrates with narrow therapeutic indices may need to be reduced when given concurrently with IBRANCE. (7.3) 7.1 Agents That May Increase Palbociclib Plasma Concentrations Effect of CYP3A Inhibitors Coadministration of a strong CYP3A inhibitor (itraconazole) increased the plasma exposure of palbociclib in healthy subjects by 87%. Avoid', 'DailyMed'),
(20679, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Palbociclib is primarily metabolized by CYP3A and sulfotransferase (SULT) enzyme SULT2A1. In vivo, palbociclib is a time-dependent inhibitor of CYP3A. •CYP3A Inhibitors: Avoid concurrent use of IBRANCE with strong CYP3A inhibitors. If the strong inhibitor cannot be avoided, reduce the IBRANCE dose. (2.2, 7.1) •CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (7.2) •CYP3A Substrates: The dose of sensitive CYP3A4 substrates with narrow therapeutic indices may need to be reduced when given concurrently with IBRANCE. (7.3) 7.1 Agents That May Increase Palbociclib Plasma Concentrations Effect of CYP3A Inhibitors Coadministration of a strong CYP3A inhibitor (itraconazole) increased the plasma exposure of palbociclib in healthy subjects by 87%. Avoid', 'DailyMed'),
(8130, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Palbociclib is primarily metabolized by CYP3A and sulfotransferase (SULT) enzyme SULT2A1. In vivo, palbociclib is a time-dependent inhibitor of CYP3A. •CYP3A Inhibitors: Avoid concurrent use of IBRANCE with strong CYP3A inhibitors. If the strong inhibitor cannot be avoided, reduce the IBRANCE dose. (2.2, 7.1) •CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (7.2) •CYP3A Substrates: The dose of sensitive CYP3A4 substrates with narrow therapeutic indices may need to be reduced when given concurrently with IBRANCE. (7.3) 7.1 Agents That May Increase Palbociclib Plasma Concentrations Effect of CYP3A Inhibitors Coadministration of a strong CYP3A inhibitor (itraconazole) increased the plasma exposure of palbociclib in healthy subjects by 87%. Avoid', 'DailyMed'),
(20677, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Palbociclib is primarily metabolized by CYP3A and sulfotransferase (SULT) enzyme SULT2A1. In vivo, palbociclib is a time-dependent inhibitor of CYP3A. •CYP3A Inhibitors: Avoid concurrent use of IBRANCE with strong CYP3A inhibitors. If the strong inhibitor cannot be avoided, reduce the IBRANCE dose. (2.2, 7.1) •CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (7.2) •CYP3A Substrates: The dose of sensitive CYP3A4 substrates with narrow therapeutic indices may need to be reduced when given concurrently with IBRANCE. (7.3) 7.1 Agents That May Increase Palbociclib Plasma Concentrations Effect of CYP3A Inhibitors Coadministration of a strong CYP3A inhibitor (itraconazole) increased the plasma exposure of palbociclib in healthy subjects by 87%. Avoid', 'DailyMed'),
(15457, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(26562, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(8563, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(8564, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(3701, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(26561, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(30085, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(25294, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(14165, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(25293, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(2421, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(30086, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(30277, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(14166, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(1691, 'drug_class', 'N/A', 'contraindicated', '7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1) Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use ', 'DailyMed'),
(7975, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(7975, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(7975, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(7975, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19328, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(19328, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19328, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19328, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19343, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(19343, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19343, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(8291, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(8291, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(8291, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17107, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(17107, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17107, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(32184, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(32184, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(32184, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(22877, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(22877, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(22877, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(22877, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(13630, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(13630, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(13630, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(13630, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17552, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(17552, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17552, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(8295, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(8295, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(8295, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(25693, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(25693, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(25693, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(25693, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17105, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(17105, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17105, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17105, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(6928, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(6928, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(6928, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17654, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(17654, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17654, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(1599, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(1599, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(1599, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(1599, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(31631, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(31631, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(31631, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17652, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(17652, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17652, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17652, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(23654, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(23654, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(23654, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(23654, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17553, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(17553, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17553, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(16190, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(16190, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(16190, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(8311, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(8311, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(8311, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(8311, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(32188, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(32188, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(32188, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(8255, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(8255, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(8255, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(7974, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(7974, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(7974, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(7974, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17653, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(17653, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17653, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17653, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17108, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(17108, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17108, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(9025, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(9025, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(9025, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(9025, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19362, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(19362, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19362, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19362, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(6775, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(6775, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(6775, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(6775, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17554, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(17554, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17554, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(7745, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(7745, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(7745, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(7745, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(31893, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(31893, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(31893, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19361, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(19361, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19361, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(19361, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(13629, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(13629, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(13629, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(13629, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(31661, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(31661, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(31661, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(32289, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(32289, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(32289, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17551, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(17551, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17551, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(30602, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(30602, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(30602, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(30602, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(29861, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(29861, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(29861, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(29861, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(30601, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(30601, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(30601, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(30601, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17106, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(17106, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17106, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(17106, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(13384, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Table 5: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. In', 'DailyMed'),
(13384, 'hydrochlorothiazide', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(13384, 'metformin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(13384, 'sitagliptin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once dailyfor 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12%[↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7%[↓22%, ↑11%] ↓22%[↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13%[↑3%, ↑24%] ↑51%[↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, r', 'DailyMed'),
(4207, 'drug_class', 'N/A', 'minor', 'Drug Interactions The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the coadministration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.', 'DailyMed'),
(27570, 'drug_class', 'N/A', 'minor', 'Drug Interactions The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the coadministration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.', 'DailyMed'),
(27571, 'drug_class', 'N/A', 'minor', 'Drug Interactions The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the coadministration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.', 'DailyMed'),
(27574, 'drug_class', 'N/A', 'minor', 'Drug Interactions The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the coadministration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.', 'DailyMed'),
(18340, 'drug_class', 'N/A', 'minor', 'Drug Interactions The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the coadministration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.', 'DailyMed'),
(18343, 'drug_class', 'N/A', 'minor', 'Drug Interactions The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the coadministration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.', 'DailyMed'),
(10932, 'drug_class', 'N/A', 'minor', 'Drug Interactions The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the coadministration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.', 'DailyMed'),
(4208, 'drug_class', 'N/A', 'minor', 'Drug Interactions The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the coadministration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.', 'DailyMed'),
(10937, 'drug_class', 'N/A', 'minor', 'Drug Interactions The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the coadministration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.', 'DailyMed'),
(17991, 'drug_class', 'N/A', 'minor', 'Drug Interactions The ototoxic effects of the aminoglycosides, including streptomycin, are potentiated by the coadministration of ethacrynic acid, furosemide, mannitol and possibly other diuretics.', 'DailyMed'),
(7311, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7311, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7311, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2774, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2774, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2774, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(33114, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(33114, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(33114, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(25300, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25300, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(25300, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(25299, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25299, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(25299, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21812, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21812, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21812, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(3867, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3867, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(3867, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(16742, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16742, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(16742, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(23352, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(23352, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(23352, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21821, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21821, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21821, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(8830, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8830, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(8830, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4648, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4648, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4648, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(22448, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22448, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(22448, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(5123, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5123, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(5123, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(29790, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29790, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(29790, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(5695, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(5695, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(5695, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4136, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4136, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4136, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(3338, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(3338, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(3338, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21232, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21232, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21232, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21170, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21170, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21170, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21222, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21222, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21222, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26020, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26020, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(26020, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(22272, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22272, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(22272, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(17251, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17251, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(17251, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(31900, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31900, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(31900, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4954, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4954, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4954, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21815, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21815, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21815, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2057, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2057, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2057, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(18253, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18253, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(18253, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(24291, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24291, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(24291, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7297, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7297, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7297, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2688, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2688, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2688, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(23369, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(23369, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(23369, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4646, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4646, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4646, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7296, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7296, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7296, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(12731, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(12731, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(12731, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(22770, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22770, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(22770, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21806, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21806, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21806, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(9335, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9335, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(9335, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2540, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2540, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2540, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(1770, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(1770, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(1770, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21816, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21816, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21816, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7299, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7299, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7299, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(16560, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(16560, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(16560, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(15780, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(15780, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(15780, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21804, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21804, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21804, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(8135, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8135, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(8135, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21813, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21813, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21813, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4587, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4587, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4587, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(8639, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(8639, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(8639, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(11847, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(11847, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(11847, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(26809, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26809, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(26809, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2061, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2061, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2061, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21827, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21827, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21827, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21805, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(21805, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21805, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(6724, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6724, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(6724, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4898, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4898, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4898, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(30132, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(30132, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(30132, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21811, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21811, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21811, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21803, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21803, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21803, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(10176, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(13098, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(13098, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(13098, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(3868, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(3868, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7312, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7312, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7312, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(23833, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(23833, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(23833, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21810, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21810, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21810, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(28382, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28382, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(28382, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21828, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21828, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21828, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(12996, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(12996, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(12996, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(26424, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(26424, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(26424, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(6722, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(6722, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(6722, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21824, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21824, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21824, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(28517, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28517, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(28517, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21822, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21822, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21822, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21801, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21801, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21801, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21808, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21808, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21808, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2619, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2619, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7294, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7294, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7294, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(18254, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(18254, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(18254, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21809, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21809, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21809, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21800, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21800, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21800, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(25301, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25301, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(25301, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7308, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7308, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7308, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7317, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(7317, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(7317, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(10333, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(10333, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(10333, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(9334, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(9334, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(9334, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(25709, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25709, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(25709, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(28676, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(28676, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(28676, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(29789, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(29789, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(29789, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(31130, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31130, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(31130, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21829, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(21829, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(21829, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(24936, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(24936, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(24936, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(29579, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(29579, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(22131, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22131, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(22131, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(23935, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(23935, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(23935, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(929, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(929, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(929, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(22271, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(22271, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(22271, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(25302, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(25302, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(25302, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(31901, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(31901, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(31901, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2006, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(2006, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(2006, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(17249, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(17249, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(17249, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4377, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4377, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4377, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4586, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Antiarrhythmic Drugs LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.', 'DailyMed'),
(4586, 'salicylic acid', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(4586, 'glycerin', 'N/A', 'minor', 'Drug Interactions Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfa', 'DailyMed'),
(3296, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Prolongation of prothrombin time occurs in patients stabilized on warfarin. Therapy with danazol may cause an increase in carbamazepine levels in patients taking both drugs. Danazol can cause insulin resistance. Caution should be exercised when used with antidiabetic drugs. Danazol may raise the plasma levels of cyclosporin and tacrolimus, leading to an increase of the renal toxicity of these drugs. Monitoring of systemic concentrations of these drugs and appropriate dose adjustments may be needed when used concomitantly with danazol. Danazol can increase the calcemic response to synthetic vitamin D analogs in primary hypoparathyroidism. The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with statins such as simvastatin, atorvast', 'DailyMed'),
(17094, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Prolongation of prothrombin time occurs in patients stabilized on warfarin. Therapy with danazol may cause an increase in carbamazepine levels in patients taking both drugs. Danazol can cause insulin resistance. Caution should be exercised when used with antidiabetic drugs. Danazol may raise the plasma levels of cyclosporin and tacrolimus, leading to an increase of the renal toxicity of these drugs. Monitoring of systemic concentrations of these drugs and appropriate dose adjustments may be needed when used concomitantly with danazol. Danazol can increase the calcemic response to synthetic vitamin D analogs in primary hypoparathyroidism. The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with statins such as simvastatin, atorvast', 'DailyMed'),
(3315, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Prolongation of prothrombin time occurs in patients stabilized on warfarin. Therapy with danazol may cause an increase in carbamazepine levels in patients taking both drugs. Danazol can cause insulin resistance. Caution should be exercised when used with antidiabetic drugs. Danazol may raise the plasma levels of cyclosporin and tacrolimus, leading to an increase of the renal toxicity of these drugs. Monitoring of systemic concentrations of these drugs and appropriate dose adjustments may be needed when used concomitantly with danazol. Danazol can increase the calcemic response to synthetic vitamin D analogs in primary hypoparathyroidism. The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with statins such as simvastatin, atorvast', 'DailyMed'),
(3297, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Prolongation of prothrombin time occurs in patients stabilized on warfarin. Therapy with danazol may cause an increase in carbamazepine levels in patients taking both drugs. Danazol can cause insulin resistance. Caution should be exercised when used with antidiabetic drugs. Danazol may raise the plasma levels of cyclosporin and tacrolimus, leading to an increase of the renal toxicity of these drugs. Monitoring of systemic concentrations of these drugs and appropriate dose adjustments may be needed when used concomitantly with danazol. Danazol can increase the calcemic response to synthetic vitamin D analogs in primary hypoparathyroidism. The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with statins such as simvastatin, atorvast', 'DailyMed'),
(17137, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Prolongation of prothrombin time occurs in patients stabilized on warfarin. Therapy with danazol may cause an increase in carbamazepine levels in patients taking both drugs. Danazol can cause insulin resistance. Caution should be exercised when used with antidiabetic drugs. Danazol may raise the plasma levels of cyclosporin and tacrolimus, leading to an increase of the renal toxicity of these drugs. Monitoring of systemic concentrations of these drugs and appropriate dose adjustments may be needed when used concomitantly with danazol. Danazol can increase the calcemic response to synthetic vitamin D analogs in primary hypoparathyroidism. The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with statins such as simvastatin, atorvast', 'DailyMed'),
(6875, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6875, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6875, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6875, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6875, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6875, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6875, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6875, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6875, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6875, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6875, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6875, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(22543, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22543, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(22543, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(22543, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(22543, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(22543, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(22543, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(22543, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(22543, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(22543, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(22543, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(22543, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6884, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6884, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6884, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6884, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6884, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6884, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6884, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6884, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6884, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6884, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6884, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6884, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(21363, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21363, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(21363, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(21363, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21363, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(21363, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(21363, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21363, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21363, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21363, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21363, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(21363, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(7005, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7005, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(7005, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(7005, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(7005, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(7005, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(7005, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(7005, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(7005, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(7005, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(7005, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(7005, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(10762, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(10762, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(10762, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(10762, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(10762, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(10762, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(10762, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(10762, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(10762, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(10762, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(10762, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(10762, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6881, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6881, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6881, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6881, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6881, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6881, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6881, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6881, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6881, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6881, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6881, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6881, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6870, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6870, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6870, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6870, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6870, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6870, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6870, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6870, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6870, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6870, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6870, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6870, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(22554, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22554, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(22554, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(22554, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(22554, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(22554, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(22554, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(22554, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(22554, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(22554, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(22554, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(22554, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(3793, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3793, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(3793, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(3793, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(3793, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(3793, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(3793, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(3793, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(3793, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(3793, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(3793, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(3793, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6877, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6877, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6877, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6877, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6877, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6877, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6877, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6877, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6877, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6877, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6877, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6877, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(22557, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22557, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(22557, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(22557, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(22557, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(22557, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(22557, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(22557, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(22557, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(22557, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(22557, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(22557, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6880, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6880, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6880, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6880, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6880, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6880, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6880, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6880, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6880, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6880, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(6880, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6880, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6900, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6900, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6900, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6900, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6900, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6900, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6900, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6900, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6900, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6900, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6900, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6900, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(21387, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21387, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(21387, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(21387, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21387, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(21387, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(21387, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21387, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21387, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21387, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21387, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(21387, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6878, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6878, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6878, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6878, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6878, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6878, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6878, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6878, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6878, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6878, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6878, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6878, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6891, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6891, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6891, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6891, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6891, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6891, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6891, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6891, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6891, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6891, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6891, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6891, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(21366, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21366, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(21366, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(21366, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21366, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(21366, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(21366, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21366, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21366, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21366, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21366, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(21366, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(28285, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28285, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(28285, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(28285, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(28285, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(28285, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(28285, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(28285, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(28285, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(28285, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(28285, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(28285, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(21436, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21436, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(21436, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(21436, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21436, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(21436, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(21436, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21436, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21436, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21436, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21436, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(21436, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(21367, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21367, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(21367, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(21367, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21367, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(21367, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(21367, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21367, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21367, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21367, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21367, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(21367, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6890, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6890, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(6890, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6890, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6890, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6890, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6890, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6890, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6890, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6890, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6890, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6890, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(264, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(264, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(264, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(264, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(264, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(264, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(264, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(264, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(264, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(264, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(264, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(264, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(260, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(260, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(260, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(260, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(260, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(260, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(260, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(260, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(260, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(260, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(260, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(260, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(18250, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(18250, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(18250, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(18250, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(18250, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(18250, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(18250, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(18250, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(18250, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(18250, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(18250, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(18250, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(21391, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21391, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(21391, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(21391, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21391, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(21391, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(21391, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21391, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21391, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21391, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21391, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(21391, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(1587, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(1587, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(1587, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(1587, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(1587, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(1587, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(1587, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(1587, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(1587, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(1587, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(1587, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(1587, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(17784, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(17784, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(17784, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(17784, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(17784, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(17784, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(17784, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(17784, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(17784, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(17784, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(17784, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(17784, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6889, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6889, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6889, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6889, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6889, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6889, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6889, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6889, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6889, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6889, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6889, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6889, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(21394, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21394, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(21394, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(21394, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21394, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(21394, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(21394, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21394, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21394, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(21394, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(21394, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(21394, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(4731, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4731, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(4731, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(4731, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(4731, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(4731, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(4731, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(4731, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(4731, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(4731, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(4731, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(4731, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6887, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6887, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6887, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6887, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6887, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6887, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6887, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6887, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6887, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6887, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6887, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6887, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(4729, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4729, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(4729, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(4729, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(4729, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(4729, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(4729, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(4729, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(4729, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(4729, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(4729, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(4729, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(19759, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(19759, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(19759, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(19759, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(19759, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(19759, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(19759, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(19759, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(19759, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(19759, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(19759, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(19759, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(4910, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4910, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(4910, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(4910, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(4910, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(4910, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(4910, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(4910, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(4910, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(4910, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(4910, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(4910, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(17619, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(17619, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(17619, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(17619, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(17619, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(17619, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(17619, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(17619, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(17619, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(17619, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(17619, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(17619, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(6803, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6803, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(6803, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(6803, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6803, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(6803, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(6803, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6803, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6803, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(6803, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(6803, 'cyclosporine', 'N/A', 'major', 'No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin.', 'DailyMed'),
(6803, 'sulopenem etzadroxil and probenecid', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Ketoprofen: Concomitant use is not recommended (7.1) See full prescribing information for additional clinically significant drug interactions with ORLYNVAH (7.1) 7. Table 2 Established and Other Potentially Clinically Significant Drug Interactions Concomitant Drug/Drug Class Effect on Drug Concentration Recommendation Ketorolac tromethamine ↑ ketorolac tromethamine Contraindicated Ketoprofen ↑ ketoprofen Concomitant use is not recommended.', 'DailyMed'),
(18849, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(18849, 'hydrochlorothiazide', 'N/A', 'minor', 'Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.', 'DailyMed'),
(18849, 'ketoprofen', 'N/A', 'minor', 'Drug Interactions The following drug interactions were studied with ketoprofen doses of 200 mg/day. The possibility of increased interaction should be kept in mind when ketoprofen immediate-release doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs. Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as the immediate-release capsules.', 'DailyMed'),
(18849, 'probenecid', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed'),
(18849, 'warfarin', 'N/A', 'minor', 'Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone 7.3 Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown c', 'DailyMed'),
(18849, 'caffeine citrate', 'N/A', 'minor', 'Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers.', 'DailyMed'),
(18849, 'leflunomide', 'N/A', 'minor', 'In patients taking leflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(18849, 'teriflunomide', 'N/A', 'minor', 'In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(18849, 'leflunomide and diclofenac sodium gel', 'N/A', 'minor', 'In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.', 'DailyMed'),
(18849, 'probenecid and colchicine', 'N/A', 'minor', 'These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin.', 'DailyMed');

